Being told that you are living with non-alcoholic steatohepatitis (NASH) can come as a bit of a shock, especially if you’ve experienced few or no symptoms of the disease. Because NASH is often symptomless, many people don’t know they have it until it leads to further problems.
*A placebo is an inactive drug that has no treatment value. In the FALCON 1 study, 1 out of every 4 participants will be assigned the placebo. As this study is ‘double-blind’ you won’t know which group you are assigned to and neither will the study team. This helps us to be sure that any changes seen are due to the study drug alone and not some other factor (such as increased monitoring).
You won’t be asked for any personal information until after you have completed the questionnaire and decided to proceed.
Research suggests that certain health conditions make you more likely to have or develop NASH. These include:
Currently, there are no approved treatment options for NASH. Many doctors recommend losing weight, as research suggests this helps to reduce the liver fat and scarring associated with the condition. However, many people struggle to make such lifestyle changes. Because of this, there is a significant need for new NASH drugs to be developed.